Step 1 topics → General Pharmacology → Efficacy vs Potency

Efficacy vs Potency

USMLE Step 1 trap: Equates higher potency with greater clinical effectiveness. Potency (EC50) reflects the dose needed for effect, not the maximum effect achievable; a less potent drug can have greater efficacy (higher Emax) and be clinically preferable.

Efficacy and potency are two completely different properties of a drug, and USMLE Step 1 loves to exploit the fact that students conflate them. Efficacy (Emax) is the maximum effect a drug can produce — the ceiling. Potency (EC50) is the dose required to produce 50% of that maximum effect — how much drug you need. A drug can be highly potent (works at tiny doses) but have low efficacy (can't produce a strong effect), or vice versa. These properties are independent of each other, and the exam tests whether you actually understand that distinction.

Step 1 tests this through two main angles: direct definition recall and — more commonly — interpretation of log dose-response curves. On these graphs, the plateau height tells you efficacy and the horizontal position of the curve tells you potency. The exam will show you curve shifts and ask what changed. A rightward shift with the same plateau? Potency decreased, efficacy unchanged. A lower plateau? Efficacy decreased. Students who memorize 'rightward shift = bad' without understanding what 'bad' means will get these wrong every time.

The trickiest part is the antagonist angle. Competitive antagonists shift the curve right (decrease potency) but preserve Emax — because you can flood the receptor with agonist and overcome the competition. Noncompetitive antagonists reduce Emax because they block receptors in a way that can't be overcome. This distinction is a classic USMLE Step 1 trap, and it requires you to think mechanistically, not just pattern-match on curve shape.

From real student decks
81%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: A more potent drug is always clinically superior to a less potent one.
Right: Potency (EC50) reflects the dose needed for effect, not the maximum effect achievable; a less potent drug can have greater efficacy (higher Emax) and be clinically preferable.
Potency just tells you the dose needed to get an effect — it says nothing about how strong that effect can be. A drug that works at nanomolar concentrations (high potency) might still hit a low ceiling (low efficacy), making it clinically useless for severe disease. Clinically, you'd almost always prefer a drug with higher efficacy even if it requires a larger dose, because you can always titrate the dose up — you can't exceed a drug's Emax no matter how much you give.
Common mistake
Wrong: A rightward shift of the dose-response curve always indicates reduced efficacy.
Right: A rightward shift indicates decreased potency (higher EC50) but Emax (efficacy) is unchanged if the curve plateaus at the same level; only a lower plateau indicates reduced efficacy.
When a dose-response curve shifts right, you have to look at what happened to the plateau — not just the shift. If the plateau stays at the same height, Emax is unchanged, meaning efficacy is preserved; you just need more drug to get there (decreased potency, higher EC50). Only when the plateau drops does efficacy decrease. Train yourself to always check two things on any shifted curve: horizontal position (potency) and plateau height (efficacy).
Common mistake
Wrong: Competitive antagonists reduce the maximum effect (Emax) of an agonist.
Right: Competitive antagonists shift the dose-response curve rightward (increase EC50) but do not reduce Emax because they can be overcome by increasing agonist concentration.
Competitive antagonists compete with agonists for the same receptor binding site, so their effect can be overcome by adding more agonist. This is why the curve shifts right — you need more agonist to hit the same response — but the maximum response (Emax) is still achievable. Noncompetitive antagonists bind irreversibly or at a separate allosteric site, permanently taking receptors out of play so no amount of agonist can restore the full response, causing Emax to drop. The key question to ask is: can the antagonism be overcome by increasing agonist?
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Define efficacy (Emax) and potency (EC50) and explain what each parameter tells you about a drug's behavior on a dose-response curve.
  2. Interpret a log dose-response curve and determine whether a shift or change in plateau reflects a change in potency, efficacy, or both.
  3. Distinguish the effect of competitive antagonists (rightward shift, preserved Emax) from noncompetitive antagonists (reduced Emax) on a dose-response curve.

Can you avoid these mistakes?

Drug A has an EC50 of 5 mg and an Emax of 80% response. Drug B has an EC50 of 50 mg and an Emax of 100% response. Which drug is more potent? Which is more efficacious? Which would you prefer for treating a severe condition?
On a log dose-response curve, you add a drug that shifts the agonist curve to the right but the plateau remains at the same level. Is this a competitive or noncompetitive antagonist? What happened to EC50 and Emax?
A patient is on an opioid agonist. You add naloxone (a competitive opioid antagonist) at a low dose. What happens to the dose-response curve of the opioid? If you dramatically increase the opioid dose, can you restore the original Emax?
Two drugs treat hypertension. Drug X lowers BP by a maximum of 20 mmHg at 10 mg. Drug Y lowers BP by a maximum of 40 mmHg but requires 200 mg to do so. A patient's BP is dangerously high and uncontrolled on Drug X at max dose — what concept explains why switching to Drug Y makes sense even though it requires a much higher dose?

Related topics

ADME and Bioavailability Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination

See how your Anki deck covers this topic.

Upload your deck for a free audit →